Gemcitabine plus capecitabine (Gem-Cape) biweekly in chemorefractory metastatic colorectal cancer.

Clin Transl Oncol · 2015 · PMC4544491 · PMID 25428757

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

showed a trendp = 0.056so close (0.05 < p ≤ 0.1)

Younger patients (<65 years) showed a trend toward better survival ( p = 0.056).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.